Gene
TMEM74B
| Entrez Gene ID | 55321 (See on NCBI) |
| Description | transmembrane protein 74B |
| Gene Synonyms | C20orf46 |
| Node consisting of this Gene | C20orf46 C20orf46///C20orf46 C20orf46///C20orf46 |
Networks including this gene
| GSE10072_top8000 - GSE10072 - SiGN-BN NNSR | Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival |
| GSE10927_top8000 - GSE10927 - SiGN-BN NNSR | Human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10), on Affymetrix HG_U133_plus_2 arrays |
| GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11135_top8000 - GSE11135 - SiGN-BN NNSR | The MILE (Microarray Innovations In LEukemia) study pre-phase |
| GSE12195_top8000 - GSE12195 - SiGN-BN NNSR | Mutations of multiple genes deregulate the NF-kB pathway in diffuse large B cell lymphoma |
| GSE12460_top8000 - GSE12460 - SiGN-BN NNSR | Expression profiling of neuroblastic tumors |
| GSE12470_top8000 - GSE12470 - SiGN-BN NNSR | Gene expression profiles of serous ovarian cancer samples |
| GSE12777_top8000 - GSE12777 - SiGN-BN NNSR | Gene expression profiling of 51 human breast cancer cell lines |
| GSE12945_top8000 - GSE12945 - SiGN-BN NNSR | Expression data from colorectal cancers |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13294_top8000 - GSE13294 - SiGN-BN NNSR | Expression data from primary colorectal cancers |
| GSE13507_top8000 - GSE13507 - SiGN-BN NNSR | Predective Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
| GSE13598_top8000 - GSE13598 - SiGN-BN NNSR | mRNA expression of 131 cancer cell lines |
| GSE13861_top8000 - GSE13861 - SiGN-BN NNSR | Gene expression signature-based novel prognostic risk score in gastric cancer |
| GSE13898_top8000 - GSE13898 - SiGN-BN NNSR | Robust prognostic biomarkers for EAC identified by systems-level characterization of tumor transcriptome |
| GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
| GSE14315_top8000 - GSE14315 - SiGN-BN NNSR | Effects of demethylation on lung cancer cell lines |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15765_top8000 - GSE15765 - SiGN-BN NNSR | Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE16391_top8000 - GSE16391 - SiGN-BN NNSR | GGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| GSE16757_top8000 - GSE16757 - SiGN-BN NNSR | Gene expression study in hepatocellular carcinoma |
| GSE16987_top8000 - GSE16987 - SiGN-BN NNSR | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
| GSE17537_top8000 - GSE17537 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (VMC Samples) |
| GSE18088_top8000 - GSE18088 - SiGN-BN NNSR | Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| GSE18105_top8000 - GSE18105 - SiGN-BN NNSR | Stage II and stage III colorectal cancer |
| GSE18684_top8000 - GSE18684 - SiGN-BN NNSR | Fine mapping of androgen regulated genes in LNCaP cells |
| GSE18842_top8000 - GSE18842 - SiGN-BN NNSR | Gene expression analysis of human lung cancer and control samples |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19188_top8000 - GSE19188 - SiGN-BN NNSR | Expression data for early stage NSCLC |
| GSE19274_top8000 - GSE19274 - SiGN-BN NNSR | Expression profiling in Neuroblastoma Primary tumors and Cell lines |
| GSE19417_top8000 - GSE19417 - SiGN-BN NNSR | Human esophageal adenocarcinomas |
| GSE19804_top8000 - GSE19804 - SiGN-BN NNSR | Genome-wide screening of transcriptional modulation in non-smoking female lung cancer in Taiwan |
| GSE20271_top8000 - GSE20271 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE21510_top8000 - GSE21510 - SiGN-BN NNSR | Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer |
| GSE21653_top8000 - GSE21653 - SiGN-BN NNSR | A gene expression signature identifies two prognostic subgroups of basal breast cancer |
| GSE22153_top8000 - GSE22153 - SiGN-BN NNSR | Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) |
| GSE22541_top8000 - GSE22541 - SiGN-BN NNSR | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23593_top8000 - GSE23593 - SiGN-BN NNSR | Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome |
| GSE23772_top8000 - GSE23772 - SiGN-BN NNSR | Why does HAMLET preferentially kill tumor cells? p38-dependent death in tumor but up-regulation of innate immunity in healthy, differentiated cells |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
| GSE25428_top8000 - GSE25428 - SiGN-BN NNSR | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE26599_top8000 - GSE26599 - SiGN-BN NNSR | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE26639_top8000 - GSE26639 - SiGN-BN NNSR | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE26906_top8000 - GSE26906 - SiGN-BN NNSR | APC colon stage II |
| GSE27480_top8000 - GSE27480 - SiGN-BN NNSR | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE29288_top8000 - GSE29288 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
| GSE29354_top8000 - GSE29354 - SiGN-BN NNSR | Mesothelioma tumor gene expression profiles |
| GSE29817_top8000 - GSE29817 - SiGN-BN NNSR | Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor (EGFR) Predicts Outcome after Chemoradiotherapy of Lymph Node Negative Cervical Cancer |
| GSE31279_top8000 - GSE31279 - SiGN-BN NNSR | Decoding differentially regulated epithelial and stromal pathways in colorectal cancer |
| GSE31547_top8000 - GSE31547 - SiGN-BN NNSR | MSKCC-A Primary Lung Cancer Specimens |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE4554_top8000 - GSE4554 - SiGN-BN NNSR | Gene expression signature of colorectal cancer with microsatellite instability. |
| GSE5107_top8000 - GSE5107 - SiGN-BN NNSR | Distinct Transcription Profiles of Primary and Secondary Glioblastomas |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6465_top8000 - GSE6465 - SiGN-BN NNSR | Expression data of Hepatocellular Carcinoma |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7604_top8000 - GSE7604 - SiGN-BN NNSR | Human Colon tumor vs Normal Human DNA |
| GSE7606_top8000 - GSE7606 - SiGN-BN NNSR | Human Melanoma vs Normal Human DNA |
| GSE8332_top8000 - GSE8332 - SiGN-BN NNSR | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE9195_top8000 - GSE9195 - SiGN-BN NNSR | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| GSE9843_top8000 - GSE9843 - SiGN-BN NNSR | Gene expression profiling of 91 hepatocellular carcinomas with hepatitis C virus etiology |
(72 networks)
